Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

NCT04186494 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Sleep Apnea, Obstructive

Interventions

DRUG: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
DEVICE: Continuous positive airway pressure treatment
COMBINATION_PRODUCT: Liraglutide and CPAP

Sponsor

St Vincent's University Hospital, Ireland

Collaborators

[object Object]
[object Object]